5 results match your criteria: "Division of Hematology Mayo Clinic Rochester Minnesota USA.[Affiliation]"
Article Synopsis
- Chronic lymphocytic leukemia (CLL) varies greatly among patients, with some experiencing slow progression and others facing aggressive forms leading to early death.
- A study with 1,154 CLL patients examined how lifestyle and medical history factors before diagnosis influenced the time until first treatment (TTFT), adjusting for the CLL-International Prognostic Index (CLL-IPI).
- Results indicated that the CLL-IPI score was the main factor affecting TTFT, with minimal influence from lifestyle factors, providing reassurance to patients about the limited impact of these factors on their disease progression.
Article Synopsis
- * There are very few documented cases of benign monoclonal gammopathy of undetermined significance (MGUS) with IgD subtype, and only two had follow-up beyond five years.
- * This report highlights a patient from those two cases who, after 26 years of follow-up, did not develop multiple myeloma or amyloidosis and died from unrelated causes, suggesting that IgD M-protein doesn’t always mean a malignant condition.
Adolescents and young adults (AYA) with lymphoma experience treatment-related effects in the short and long term that impact their quality of life and survivorship experience. The effort to improve outcomes for AYA lymphoma survivors requires understanding the available literature, identifying current knowledge deficits, designing better clinical trials incorporating the patient perspective, using novel tools to bridge data gaps and building survivorship guidelines that translate research to clinical practice. This review article summarizes the current state of lymphoma treatment-related outcomes in AYAs and provides future direction.
View Article and Find Full Text PDFFirst report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma.
EJHaem
November 2023
Community Health Network MD Anderson Indianapolis Indiana USA.
Health-related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT-Leu and EQ-5D-3L questionnaires in the Connect CLL Registry, a large, US-based, multicenter, prospective observational study of CLL patients enrolled between 2010 and 2014, prior to the introduction of novel therapies.
View Article and Find Full Text PDF